Yeon Jae Woo
Research Subjects
Research Interests
Yeon Jae Woo has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Byeong-Gwan Ha
Yonsei University College of Medicine, Seoul, Korea
1 shared publication - Byung Moon Kim
Department of Radiology, Yonsei University College of Medicine, Seoul, Korea
1 shared publication - Heeyeon Kim
Department of Psychiatry, Yongin Severance Hospital, Yonsei University College of Medicine, Yongin, Republic of Korea
1 shared publication - Hye Jeong Kim1 shared publication
- Hyerin Jo1 shared publication
- HyunKyung Shin
Research Institute of Minds.AI, Co. Ltd., Seoul, Republic of Korea
1 shared publication
Latest Publications
- Open Access
- 13 November 2025
- Published by JMIR Publications Inc. in JMIR Preprints
Efficacy and Usability of a Virtual Reality-Based Cognitive Behavioral Therapy Program (CHEEU. Forest N) for Patients with Major Depressive Disorder: A Randomized, Non-inferiority Confirmatory Trial (Preprint)
BACKGROUND Major depressive disorder (MDD) poses a substantial global health burden, with a high suicide risk and limited treatment accessibility. Although cognitive behavioral therapy (CBT) shows robust efficacy, practical barriers, including therapist availability and time constraints, limit its implementation. Virtual reality (VR)-based interventions offer an immersive and accessible alternative. However, rigorous evidence for VR-based CBT for depression remains limited. OBJECTIVE To evaluate the efficacy and usability of CHEEU. Forest N, a VR-based CBT program integrating components of mindfulness-based cognitive, mentalization-based, and dialectical behavior therapies, compared with standard pharmacotherapy in patients with MDD. METHODS This multicenter, randomized, parallel-group, assessor-blinded, non-inferiority confirmatory trial enrolled 134 adults aged between 19 and 55 years who met the DSM-5 criteria for MDD with Patient Health Questionnaire-9 scores ≥7 and moderate suicidality. The participants were randomized 1:1 to receive 6 weekly VR-based CBT sessions (VR group, n=67) or standard antidepressant treatment with brief clinical interviews (treatment-as-usual; TAU group, n=67). The primary outcome was the change in the Korean version of the Quick Inventory of Depressive Symptomatology-Clinician-Rated (K-QIDS-C) scores from baseline to post-treatment (week 6), with a non-inferiority comparison. The secondary outcomes included self-reported depression, anxiety, stress, suicidality, quality of life, presence, and usability. The per-protocol analysis included 116 participants (58 in each group). RESULTS Both groups demonstrated a significant reduction in the severity of their depressive symptoms. The adjusted between-group difference in K-QIDS-C scores was 0.13 points (SE=0.91, 95% CI: –1.66 to 1.93, p=.883), confirming non-inferiority of VR to TAU (upper CI bound 1.93<5.0). Response rates were comparable between the VR (44.8%) and TAU (43.1%) groups (χ²=0.04, p=.852), as were the remission rates (25.9% vs. 27.6%, χ²=0.04, p=.834). For suicidality, 50% of the VR participants achieved remission compared with 43% in TAU (χ²=0.55, p=.457). No significant between-group differences emerged for the secondary outcomes, including anxiety, stress, or quality of life. Usability ratings were high (mean composite score 3.73±0.62/5.0), with participants reporting increased depression literacy (7.43±1.94/10) and willingness to recommend the program (7.47±2.01/10). Simulator sickness decreased significantly with repeated exposure. Baseline presence was correlated with usability (r=0.46, p<.001) but not with clinical outcomes. No serious adverse events occurred. CONCLUSIONS The VR-based CBT intervention demonstrated therapeutic efficacy equivalent to that of standard pharmacotherapy in treating depression, particularly in reducing suicidal ideation and increasing user satisfaction. These findings support VR-based digital therapeutics as safe, effective, and accessible alternatives or adjunctive treatment options for depression, warranting further investigation of long-term outcomes. CLINICALTRIAL This trial was registered with the Clinical Research Information Service (KCT0009868).
- 13 November 2025
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessEfficacy and Usability of a Virtual Reality-Based Cognitive Behavioral Therapy Program (CHEEU. Forest N) for Patients with Major Depressive Disorder: A Randomized, Non-inferiority Confirmatory Trial (Preprint)
BACKGROUND Major depressive disorder (MDD) poses a substantial global health burden, with a high suicide risk and limited treatment accessibility. Although cognitive behavioral therapy (CBT) shows robust efficacy, practical barriers, including therapist availability and time constraints, limit its implementation. Virtual reality (VR)-based interventions offer an immersive and accessible alternative. However, rigorous evidence for VR-based CBT for depression remains limited. OBJECTIVE To evaluate the efficacy and usability of CHEEU. Forest N, a VR-based CBT program integrating components of mindfulness-based cognitive, mentalization-based, and dialectical behavior therapies, compared with standard pharmacotherapy in patients with MDD. METHODS This multicenter, randomized, parallel-group, assessor-blinded, non-inferiority confirmatory trial enrolled 134 adults aged between 19 and 55 years who met the DSM-5 criteria for MDD with Patient Health Questionnaire-9 scores ≥7 and moderate suicidality. The participants were randomized 1:1 to receive 6 weekly VR-based CBT sessions (VR group, n=67) or standard antidepressant treatment with brief clinical interviews (treatment-as-usual; TAU group, n=67). The primary outcome was the change in the Korean version of the Quick Inventory of Depressive Symptomatology-Clinician-Rated (K-QIDS-C) scores from baseline to post-treatment (week 6), with a non-inferiority comparison. The secondary outcomes included self-reported depression, anxiety, stress, suicidality, quality of life, presence, and usability. The per-protocol analysis included 116 participants (58 in each group). RESULTS Both groups demonstrated a significant reduction in the severity of their depressive symptoms. The adjusted between-group difference in K-QIDS-C scores was 0.13 points (SE=0.91, 95% CI: –1.66 to 1.93, p=.883), confirming non-inferiority of VR to TAU (upper CI bound 1.93<5.0). Response rates were comparable between the VR (44.8%) and TAU (43.1%) groups (χ²=0.04, p=.852), as were the remission rates (25.9% vs. 27.6%, χ²=0.04, p=.834). For suicidality, 50% of the VR participants achieved remission compared with 43% in TAU (χ²=0.55, p=.457). No significant between-group differences emerged for the secondary outcomes, including anxiety, stress, or quality of life. Usability ratings were high (mean composite score 3.73±0.62/5.0), with participants reporting increased depression literacy (7.43±1.94/10) and willingness to recommend the program (7.47±2.01/10). Simulator sickness decreased significantly with repeated exposure. Baseline presence was correlated with usability (r=0.46, p<.001) but not with clinical outcomes. No serious adverse events occurred. CONCLUSIONS The VR-based CBT intervention demonstrated therapeutic efficacy equivalent to that of standard pharmacotherapy in treating depression, particularly in reducing suicidal ideation and increasing user satisfaction. These findings support VR-based digital therapeutics as safe, effective, and accessible alternatives or adjunctive treatment options for depression, warranting further investigation of long-term outcomes. CLINICALTRIAL This trial was registered with the Clinical Research Information Service (KCT0009868).